drugset / Trial / NCT00917293
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridoxal 5'-Phosphate | Unknown | 500 mg | Oral |